Moderna Inc. Research & Ratings | MRNA | Barron's

Moderna Inc. research and ratings by Barron's. View MRNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

$40.00
OFF

Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

2 weeks from now

9 hours ago · Ratings for Moderna MRNA were provided by 10 analysts in the past three months, ... Wolfe Research: Announces: Underperform: $40.00-Gena Wang: Barclays: Lowers: …

benzinga.com

60%
OFF

Moderna's MRNA Technology Looks Undervalued Despite Lower …

2 weeks from now

1 day ago · We assume a 60% probability of approval for Merck and Moderna's personalized cancer vaccine, mRNA-4157, and we expect Moderna could record $3 billion in sales from the …

morningstar.com

$41.00
OFF

Moderna’s Financial Outlook Dims Amid Vaccine ... - Markets Insider

2 weeks from now

3 days ago · In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a price target of $41.00. …

businessinsider.com

6%
OFF

Moderna Shares Surge After Barron's Highlights Undervaluation …

2 weeks from now

Jan 3, 2025 · As we step into 2025, Moderna's recent 5.6% surge signals a potential turnaround after a challenging year. With analysts projecting a 54.73% upside and promising vaccine …

folikoinsights.com

65%
OFF

Summary - MRNA - NASDAQ - Weiss Ratings

2 weeks from now

Jan 8, 2025 · Moderna, Inc. MRNA. $47.53 $4.96 11.65%. Recommendation. Sell. Prev Close. $41.58. Volume. 22,592,323. Avg Vol (90D) 6,991,635. ... Barron's says 1/7/2025 - TipRanks …

weissratings.com

12%
OFF

Moderna Stock Jumps 12%: Sell The News Or Buy The Future?

2 weeks from now

Jan 7, 2025 · Shares of Moderna Inc. NASDAQ: MRNA surged over 12% after news of the first confirmed death from the H5N1 bird flu in the United States. At one point, the stock had …

marketbeat.com

94%
OFF

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?

2 weeks from now

1 day ago · Moderna stock peaked at 497.49 in August 2021, at the height of the Covid pandemic. Since then, the stock has fallen precipitously, down 94% over the past four years. Is Moderna …

investors.com

FAQs about Moderna Inc. Research & Ratings | MRNA | Barron's Coupon?

Should you buy Moderna (mRNA – research report)?

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a price target of $41.00. Tim Anderson has given his Sell rating due to a combination of factors affecting Moderna’s financial outlook. ...

When did Moderna (mRNA) last announce earnings?

Moderna (NASDAQ:MRNA) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on MRNA's earnings history. Did Moderna beat their earnings estimates last quarter? In the previous quarter, Moderna (NASDAQ:MRNA) reported $0.03 earnings per share (EPS) to beat the analysts' consensus estimate of ($1.89) by $1.92. ...

What is Moderna’s mRNA technology?

Moderna is a pioneer in mRNA technology, which Chinese firms have been uged to consider. Photo: Reuters began, China invested big in what it saw as the safest bet – inactivated vaccines. ...

Why has Tim Anderson rated Moderna a sell?

Tim Anderson has given his Sell rating due to a combination of factors affecting Moderna’s financial outlook. Moderna’s sales forecasts for 2024 and 2025 have been revised downward, reflecting challenges in the COVID-19 market and the limited adoption of their RSV vaccine. ...